BMS-754807
产品说明书
 |
同义名 : | - |
| CAS号 : | 1001350-96-4 | |
| 货号 : | A184967 | |
| 分子式 : | C23H24FN9O | |
| 纯度 : | 99%+ | |
| 分子量 : | 461.495 | |
| MDL号 : | MFCD18633202 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(227.52 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
2% DMSO+30% PEG 300+water 5 mg/mL |
| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | IGF-1R (insulin-like growth factor-1 receptor) plays a key role in transformation, growth and survival of malignant cells, and has been considered as a general and promising target for cancer treatment. BMS-754807 is a multi-target tyrosine kinase inhibitor, most potent to IGF-1R and IR with IC50 values of 1.8nM and 1.7nM, as well as showed less potency to Met, RON, TrkA, TrkB, AurA, and AurB with IC50 values of 6, 44, 7, 4, 9, and 25nM, respectively[1]. BMS-754807 could inhibit the phosphorylation of IGF-1R and the downstream AKT and MAPK (ERK) with IC50 values of 13nM, 22nM and 13nM, as well as showed anti-proliferation with IC50 of 7nM in IGF-Sal cell line[2]. BMS-754807 at concentration of 50nM for >4h induced apoptosis, shown by cleaved PARP and Caspase 3 as well as sub-G1 arrest, in Rh41 cells. BMS-754807 exhibited inhibition on cell growth of a broad range of tumor cell lines of various histologic origins including Ewing's, rhabdomyosarcoma, neuroblastoma, liposarcoma, breast, lung, pancreatic, colon, gastric, multiple myeloma and leukemia, with IC50 ranging in 5-365nM in most cell lines. Consistent with this, BMS-754807 showed in vivo antitumor activity in various preclinical tumor models in mice and efficient to a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with tumor growth inhibition ranging in 53% to 115% after oral administration of BMS-754807 at dose ranging in 3.1-50mg/kg. As BMS-754807 inhibited both IGF-1R and IR, an oral glucose tolerance test showed that increased serum glucose level to 1.1-1.6 fold within 1h posttreatment could be observed in rodents dosed of 3.125 and 12.5mg/kg BMS-754807 at 30min before glucose challenge, with remained elevated insulin level by 2h posttreatment[1]. | ||
| 作用机制 | BMS-754807 is a reversible ATP-competitive antagonist of IGF-1R and inhibits the catalytic domain of the IGF-1R.[2] | ||
| 细胞研究 | |||||
|---|---|---|---|---|---|
| 细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
| 1483 | ~5 μM | Growth inhibitory assay | IC50=2.19 μM | 19996272 | |
| 151-B | ~5 μM | Growth inhibitory assay | IC50=2.67 μM | 19996272 | |
| 22-r-1 | ~5 μM | Growth inhibitory assay | IC50=0.175 μM | 19996272 | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.17mL 0.43mL 0.22mL |
10.83mL 2.17mL 1.08mL |
21.67mL 4.33mL 2.17mL |
